Welcome to our dedicated page for SI-BONE SEC filings (Ticker: SIBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SI-BONE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SI-BONE's regulatory disclosures and financial reporting.
SI-BONE, Inc. (SIBN) director Jeffrey W. Dunn reported exercising options for a total of 20,000 shares of common stock at an exercise price of $4.68 per share on September 1, 2026, and selling the same 20,000 shares at a weighted-average price of $18.908 per share pursuant to a Rule 10b5-1 trading plan. He also reports 81,073 shares held indirectly by The Jeffrey W. Dunn Living Trust and holdings that include 10,957 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. (SIBN) reported that Chief Executive Officer and director Laura Francis, through The David & Laura Joint Rev Tr., sold 25,972 shares of common stock on 2026-08-24 at a weighted-average price of $20.1215 per share, in transactions ranging from $20.00 to $20.24, pursuant to a Rule 10b5-1 trading plan dated May 21, 2026. Following this sale, the trust holds 291,491 shares indirectly, and Francis also has 493,900 shares held directly, including 355,697 shares issuable upon settlement of restricted stock units, each RSU representing a right to receive one share of common stock.
SI-BONE, Inc. (SIBN) reported that Anshul Maheshwari, its Chief Operating & Financial Officer, sold 11,636 shares of common stock on 2026-08-24 at a weighted-average price of $20.1075 per share under a Rule 10b5-1 trading plan dated December 17, 2025. After this sale, Maheshwari directly holds 223,284 shares, which include 167,604 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. (SIBN) insider Anshul Maheshwari, an officer, has filed a notice to sell 11,636 shares of common stock through broker Morgan Stanley Smith Barney LLC. The proposed sale has an approximate aggregate value of $232,254.56 and is to be effected on or before 08/24/2026 on NASDAQ.
The shares to be sold were acquired upon vesting of restricted stock units (RSUs) and performance stock units (PSUs) during the period from 01/01/2025 through 02/15/2026. The notice also lists recent sales over the past three months under or associated with a Rule 10b5-1 trading plan.
SI-BONE, Inc. (SIBN) is the issuer for a planned sale of its common stock reported by the DAVID & LAURA FRANCIS JOINT REV TRU/A DTD 01/03/2003 under Rule 144. The trust has filed to sell 25,972 shares of common stock that were acquired upon vesting of restricted stock units beginning 05/15/2021.
The notice also lists recent sales over the past three months, including Rule 10b5-1 plan transactions by the trust and separate sales by Laura Francis.
SI-BONE, Inc. (SIBN) reported that a trust associated with Chief Executive Officer and director Laura Francis sold shares of Common Stock under a Rule 10b5-1 trading plan dated May 21, 2026. On August 20, 2026, the trust sold 51,884 shares at a weighted-average price of $19.46 per share, in multiple transactions ranging from $19.10 to $19.73. On August 21, 2026, it sold an additional 3,923 shares at a weighted-average price of $20.02, in trades ranging from $20.00 to $20.05. Following these transactions, Laura Francis directly holds 493,900 shares, including 355,697 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. (SIBN) insider Anshul Maheshwari, Chief Op & Financial Officer, reported open-market sales of company common stock under a Rule 10b5-1 trading plan dated December 17, 2025. He sold 5,747 shares on August 19, 2026 at a weighted-average price of $19.55 and 11,228 shares on August 21, 2026 at a weighted-average price of $20.02, for total reported sales of 16,975 shares. Following these transactions, his direct holdings include 167,604 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. (SIBN) received a notice that the DAVID & LAURA FRANCIS JOINT REVOCABLE TRUST dated 01/03/2003 intends to sell 3,923 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC. The shares have an aggregate market value of $76,420.04 based on the stated market price.
The notice indicates SI-BONE had 44,818,575 shares of common stock outstanding. The securities to be sold include 1,901 shares from Performance Stock Units and 2,022 shares from Restricted Stock Units. In the past three months, the trust and Laura Francis reported prior Rule 10b5-1-related and other sales of common stock.
SI-BONE, Inc. (SIBN) insider Anshul Maheshwari filed a notice of proposed sale of company common stock under Rule 144. The notice covers 11,228 shares of common stock, with an indicated aggregate market value of $218,721.44. The shares were acquired upon vesting of restricted stock units and performance stock units during the period from 01/01/2025 through 02/15/2026. Prior sales under a 10b5-1 trading plan over the past three months totaled several thousand shares of SI-BONE common stock.
SI-BONE, Inc. (SIBN) has a notice of proposed sale of securities under Rule 144 filed for the account of the David & Laura Francis Joint Revocable Trust. The trust plans to sell up to 51,884 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,033,010.44 and with 44,818,575 shares outstanding as referenced in the notice. The shares were acquired upon vesting of restricted stock units between 05/15/2021 and 11/15/2025. The filing also notes a prior sale by Laura Francis in the past three months of 14,956 shares of common stock for $279,064.67.